Drug Efficacy Assay

The Drug Efficacy Assay evaluates the therapeutic potential of new anticancer drugs by using three-dimensional human cancer models, ensuring early detection of antitumor activity critical for drug development.

Purpose of the Test

By employing advanced in vitro clinically relevant cancer models that replicate the complex architecture and microenvironment of tumors, this assay assesses the efficacy of new therapeutic compounds administered via the cancer on chip platform. The drug circulation perfectly mimics the systemic drug delivery, allowing robust monitoring of drug-induced reductions in tumor viability via omics and histological analysis.

In alignment with recent guidelines from regulatory bodies such as the FDA and EMA, this assay is instrumental in preclinical evaluation. It enables rigorous assessment of therapeutic efficacy, ensuring that promising drug candidates are thoroughly characterized before advancing to clinical trials, thereby reducing reliance on animal models.

The MIVO® Advantage: A Superior Predictive Model

This innovative platform enhances traditional static assays by integrating dynamic fluid flow and 3D cancer models to simulate systemic drug administration and proper penetration into the tumor matrix. The continuous circulation improves drug transport and distribution within the 3D tumor model, yielding efficacy data that closely correlate with in vivo outcomes (ref drug efficacy).

Our Unique Value Proposition

Realistic 3D Tumor Microenvironment: Unlike traditional lab-on-chip systems, MIVO® technology truly supports 3D cultures, making it a breakthrough technology for histology and omics—essential tools at the forefront of tissue complexity and drug response analysis. With the ability to host spheroids, organoids, and biopsies, MIVO® faithfully replicates the in vivo environment, preserving tissue architecture and cell behavior in 3D. This is key for obtaining highly predictive and reliable data.

Dynamic Fluid Flow for Enhanced Drug Delivery: By incorporating a fluid dynamic system that mimics systemic circulation, the platform ensures improved drug delivery, resulting in more uniform drug distribution and effective penetration into the tumor tissue as in vivo.

Quantitative Evaluation of Therapeutic Efficacy: The assay delivers robust, quantitative measurements of tumor viability reduction, thereby facilitating the optimization of dosing regimens and providing critical insights into the antitumor potential of new drug candidates.